Acurx Pharmaceuticals Inc (ACXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 7,556 | 3,707 | 7,474 | 9,112 | 12,959 |
| Receivables | 48 | 51 | 129 | N/A | N/A |
| TOTAL | $7,690 | $3,858 | $7,709 | $9,377 | $13,254 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $7,690 | $3,858 | $7,709 | $9,377 | $13,254 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,421 | 3,243 | 3,042 | 2,062 | 844 |
| TOTAL | $2,421 | $3,243 | $3,042 | $2,062 | $844 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $2,421 | $3,243 | $3,042 | $2,062 | $844 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 2,855 | 1,102 | 788 | 582 | 512 |
| Common Shares | 2 | 1 | 15 | 12 | 10 |
| Retained earnings | -75,289 | -67,322 | -53,219 | -38,641 | -26,548 |
| TOTAL | $5,269 | $615 | $4,667 | $7,315 | $12,410 |
| Total Liabilities And Equity | $7,690 | $3,858 | $7,709 | $9,377 | $13,254 |